Latest News on TXG

Financial News Based On Company


Advertisement
Advertisement

T. Rowe Price reports a 10x Genomics (TXG) stake with sole voting power over 16.8M shares.

https://www.stocktitan.net/sec-filings/TXG/schedule-13g-a-10x-genomics-inc-amended-passive-investment-disclosure-9c64a1ee7e48.html
T. Rowe Price Associates, Inc. has filed an amended Schedule 13G/A report indicating a beneficial ownership of 17,472,941 shares, or 14.5%, of 10x Genomics (TXG) common stock as of September 30, 2026. The firm holds sole voting power over 16,779,529 shares and sole dispositive power over all 17,472,941 shares. T. Rowe Price explicitly stated that this report is not an admission of beneficial ownership.

10x Genomics (TXG) CEO contributes stock valued at $62.90 a share to an exchange fund.

https://www.stocktitan.net/sec-filings/TXG/form-4-10x-genomics-inc-insider-trading-activity-9ebb7dce7ba3.html
10x Genomics, Inc. CEO and director Serge Saxonov contributed 31,000 Class A common shares to an exchange fund on November 10, 2026, receiving fund shares in return. The shares were valued at $62.90 each for the transaction. Following this, Saxonov directly holds 1,019,249 shares, with additional indirect holdings through various trusts.

Instrument revenue fell 43%, yet 10x Genomics (TXG) narrowed its Q3 net loss.

https://www.stocktitan.net/sec-filings/TXG/10-q-10x-genomics-inc-quarterly-earnings-report-af7c6e80f727.html
10x Genomics (TXG) reported a narrowed net loss of $19.4 million in Q3 2026, compared to $27.5 million a year prior, despite a 43% drop in instrument revenue. Overall revenue slightly increased by 1% to $150.7 million, primarily driven by a 5% increase in consumables revenue and an 11% rise in service revenue. For the first nine months of 2026, the company's net loss widened to $50.8 million, and total revenue decreased by 5% due to significantly lower license and royalty revenue compared to the previous year.

Director Joseph E. Gilliam reports 31 directly owned Class A shares in 10x Genomics (TXG).

https://www.stocktitan.net/sec-filings/TXG/form-3-10x-genomics-inc-initial-statement-of-beneficial-ownership-83662b31fb72.html
Joseph E. Gilliam, a director at 10x Genomics, Inc. (TXG), reported direct ownership of 31 shares of Class A Common Stock. This information was disclosed in a Form 3 filing with the SEC on November 6, 2026, detailing holdings as of October 28, 2026. The filing indicates a neutral sentiment and moderate impact on the market.

10x Genomics raises FY26 sales guidance to $625M-$635M

https://scanx.trade/stock-market-news/companies/10x-genomics-raises-fy26-sales-guidance-625m-635m/55463835
10x Genomics has increased its fiscal year 2026 sales guidance to a range of $625 million to $635 million, up from the previous outlook of $610 million to $630 million. This revised guidance exceeds the consensus analyst estimate of $619.854 million, indicating stronger-than-expected performance trends. The upward adjustment suggests improved visibility on demand and a reduction in downside risk for the company's financial year.
Advertisement

Technical Analysis of 10x Genomics Inc Class A (XETR:1KJ)

https://www.tradingview.com/symbols/XETR-1KJ/technicals/
This article provides a technical analysis of 10x Genomics Inc Class A (XETR:1KJ) using various indicators like moving averages and oscillators. It presents a summary gauge indicating buy, sell, or neutral signals across different timeframes. The analysis also explains technical ratings, pivots, and the reliability of technical analysis with its limitations.

10x Genomics, Inc. Class A Common Stock (TXG)

https://milkroad.com/assets/txg/
This article provides a detailed overview of 10x Genomics, Inc. (TXG) Class A Common Stock, including key financial metrics like market cap, P/E ratio, annual revenue, and dividend yield. It also highlights major institutional holders such as Cathie Wood's ARK Investment Management, Ken Griffin's Citadel Advisors, and Jim Simons' Renaissance Technologies, detailing their ownership percentages and recent activity. The stock's price performance and next earnings date are also included.

1KJ Forecast — Price Target — Prediction for 2027

https://www.tradingview.com/symbols/XETR-1KJ/forecast-price-target/
This article provides a forecast and price target for 10x Genomics Inc Class A (1KJ) stock, based on analysis from 14 analysts. It details the current stock price, historical performance, future price estimates, earnings information, and other financial statistics for the company. The report also addresses frequently asked questions about the stock.

10x Genomics Inc Class A Estimates – FWB:1KJ

https://www.tradingview.com/symbols/FWB-1KJ/financials-estimates/
This article provides an overview of financial actuals and analyst estimates for 10x Genomics Inc Class A (FWB:1KJ) on the Frankfurt Stock Exchange. It details where users can explore reported financial data, compare actual results with estimates across income statements, balance sheets, cash flow statements, and valuation metrics, and visualize trends over time. The content emphasizes that this information is not investment advice and encourages users to conduct their own research.

Net debt of 10x Genomics Inc Class A – XETR:1KJ

https://www.tradingview.com/symbols/XETR-1KJ/financials-balance-sheet/net-debt/
This article provides financial information for 10x Genomics Inc Class A (XETR:1KJ), specifically focusing on its net debt. The content is presented within the TradingView platform, offering an overview of the company's financials without specific figures in the provided text. It highlights that the market was closed at the time of the report.
Advertisement

EBIT of 10x Genomics Inc Class A – XETR:1KJ

https://www.tradingview.com/symbols/XETR-1KJ/financials-income-statement/ebit/
This article provides the EBIT (Earnings Before Interest and Taxes) for 10x Genomics Inc Class A, traded on XETR under the symbol 1KJ. It indicates that the market is currently closed with no trades. The content primarily focuses on financial data for this specific company.

Las ETF que invierten en acciones de 10x Genomics Inc Class A

https://es.tradingview.com/symbols/XETR-1KJ/etfs/
This article lists various Exchange Traded Funds (ETFs) that hold shares of 10x Genomics Inc Class A, ordered by market value. It provides details such as the ETF symbol, market value, percentage weight of 10x Genomics, issuer, management style, expense ratio, assets under management (AUM), current price, daily percentage change, relative volume, and 3-year total return. The information aims to help investors identify funds that offer exposure to 10x Genomics with diversified opportunities and potentially lower risk.

10x Genomics Inc Class A Actuals & Estimates (XETR:1KJ)

https://www.tradingview.com/symbols/XETR-1KJ/forecast-actuals-and-estimates/
This article provides an overview of 10x Genomics Inc Class A (1KJ) stock, including its current price, performance, and analyst forecasts. It details financial actuals and estimates for the income statement, balance sheet, and cash flow, alongside answers to frequently asked questions regarding its market cap, earnings, revenue, and dividend policy.

Taxes of 10x Genomics Inc Class A – XETR:1KJ

https://www.tradingview.com/symbols/XETR-1KJ/financials-income-statement/income-tax/
This article provides financial information specifically about the taxes of 10x Genomics Inc Class A (XETR:1KJ). It indicates that the market for this stock was closed with no trades. The content is primarily a placeholder for financial data, stating "Period Value Change Change %" for taxes, with no actual figures provided in the current view.

Revenue per share of 10x Genomics Inc Class A – XETR:1KJ

https://www.tradingview.com/symbols/XETR-1KJ/financials-statistics-and-ratios/revenue-per-share/
This article focuses on the revenue per share data for 10x Genomics Inc Class A (XETR:1KJ). It appears to be a stub or a placeholder page from TradingView, indicating that the market is closed with no trades currently. The page provides an overview of the company's financials, documents, news, and community discussions.
Advertisement

Average basic shares outstanding of 10x Genomics Inc Class A – HAN:1KJ

https://www.tradingview.com/symbols/HAN-1KJ/financials-income-statement/basic-shares-outstanding/
This page provides financial data, specifically the average basic shares outstanding, for 10x Genomics Inc Class A (HAN:1KJ) traded on the Hannover Stock Exchange. The market was closed at the time of viewing, showing no trades. The data is presented in a table format indicating the period, value, and change.

ARK and Catherine D. Wood report ownership above 5% in 10x Genomics (TXG).

https://www.stocktitan.net/sec-filings/TXG/schedule-13g-a-10x-genomics-inc-amended-passive-investment-disclosure-ff62d427ad2c.html
ARK Investment Management LLC and Catherine D. Wood have reported a beneficial ownership of 5.22% in 10x Genomics (TXG), totaling 6,272,998 Class A common shares as of September 30, 2026. The SEC filing, a Schedule 13G/A, details that ARK holds sole voting power over a majority of these shares, while Catherine D. Wood has shared voting and dispositive power over the aggregate amount. This disclosure highlights their passive investment in the company.

Enterprise value to EBITDA forward of 10x Genomics Inc Class A – HAN:1KJ

https://www.tradingview.com/symbols/HAN-1KJ/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/
This article provides the enterprise value to EBITDA forward for 10x Genomics Inc Class A (HAN:1KJ) traded on the Hannover Stock Exchange. It indicates that the market is closed with no trades. The content is primarily a financial data point without further analysis or detailed reporting.

Gross margin % of 10x Genomics Inc Class A – HAN:1KJ

https://www.tradingview.com/symbols/HAN-1KJ/financials-statistics-and-ratios/gross-margin/
The article presents the gross margin percentage for 10x Genomics Inc Class A, traded on the Hannover Stock Exchange under the ticker 1KJ. It indicates that the market is currently closed with no trades recorded. The content is primarily a financial data point from TradingView.

Return on assets % of 10x Genomics Inc Class A – HAN:1KJ

https://www.tradingview.com/symbols/HAN-1KJ/financials-statistics-and-ratios/return-on-assets/
The article provides financial data specifically focusing on the "Return on assets %" for 10x Genomics Inc Class A (HAN:1KJ), traded on the Hannover Stock Exchange. It indicates that the market is closed with no recent trades. The page is primarily a financial data point within a larger trading platform.
Advertisement

Basic earnings per share (basic EPS) of 10x Genomics Inc Class A – HAN:1KJ

https://www.tradingview.com/symbols/HAN-1KJ/financials-income-statement/earnings-per-share-basic/
This article presents the basic earnings per share (basic EPS) for 10x Genomics Inc Class A (HAN:1KJ). It provides a snapshot of this financial metric, indicating the company's profitability per outstanding share, without further elaboration or historical data within the visible content. The information is sourced from TradingView and various financial data providers.

10x genomics director Shehnaaz Suliman sells $464,667 in stock

https://www.investing.com/news/insider-trading-news/10x-genomics-director-shehnaaz-suliman-sells-464667-in-stock-93CH-4916258
Shehnaaz Suliman, a director at 10x Genomics Inc. (NASDAQ:TXG), sold 5,723 shares of company stock for approximately $464,667 on September 22, 2026, under a Rule 10b5-1 trading plan. This sale occurred while the stock was trading near its 52-week high, despite InvestingPro analysis suggesting it is overvalued. The company recently reported a 3% revenue increase for Q2 2026 and an adjusted loss per share of $0.14, outperforming analyst expectations, though future prospects are viewed with a mix of optimism and caution due to the transition to the new Atera platform.

At $77.75 to $82.53 a share, 10x Genomics (TXG) CEO made five sales under a trading plan.

https://www.stocktitan.net/sec-filings/TXG/form-4-10x-genomics-inc-insider-trading-activity-b9474c62da35.html
10x Genomics, Inc. (TXG) CEO Serge Saxonov sold a total of 25,000 Class A common shares across five direct transactions on September 22, 2026. These sales were executed under a Rule 10b5-1 trading plan adopted in November 2025, with weighted-average sale prices ranging from $78.2284 to $82.3650 per share. Following these transactions, Saxonov's direct holdings amount to 1,050,249 Class A Common Stock shares, with additional indirect holdings through various trusts.

10x genomics director Shehnaaz Suliman sells $464,667 in stock By Investing.com

https://ca.investing.com/news/stock-market-news/10x-genomics-director-shehnaaz-suliman-sells-464667-in-stock-93CH-4852648
Shehnaaz Suliman, a director at 10x Genomics Inc. (NASDAQ:TXG), sold 5,723 shares of the company's stock for approximately $464,667 on September 22, 2026, under a Rule 10b5-1 trading plan. The sale occurred as the stock trades near its 52-week high after a significant surge. Despite recent positive financial results, the stock is considered overvalued by InvestingPro analysis, with mixed analyst views on its future prospects.

Under a trading plan, a 10x Genomics (TXG) director sells 5,723 shares in five transactions.

https://www.stocktitan.net/sec-filings/TXG/form-4-10x-genomics-inc-insider-trading-activity-c779d836db22.html
10x Genomics, Inc. director Suliman Shehnaaz sold a total of 5,723 shares of Class A Common Stock across five separate transactions on September 22, 2026. These sales were conducted under a Rule 10b5-1 trading plan established on March 13, 2026. The shares were sold at weighted average prices ranging from $78.1959 to $82.2768 per share.
Advertisement

5,723 10x Genomics (NASDAQ: TXG) shares set for Rule 144 sale

https://www.stocktitan.net/sec-filings/TXG/144-10x-genomics-inc-sec-filing-fe61bb8e05aa.html
An affiliate of 10x Genomics (NASDAQ: TXG), Shehnaaz Suliman, plans to sell 5,723 shares of Class A common stock under Rule 144, valued at approximately $452,689.20. The shares were acquired through RSU awards vesting between August 2024 and May 2025. J.P. Morgan Securities LLC will act as the broker for this sale, and a previous sale of the same number of shares by Suliman occurred on August 24, 2026, generating $140,477.91.

Price to earnings forward of 10x Genomics Inc Class A – LS:A2PPQJ

https://www.tradingview.com/symbols/LS-A2PPQJ/financials-statistics-and-ratios/price-earnings-fwd/
This article displays the "Price to earnings forward" for 10x Genomics Inc Class A (LS:A2PPQJ) on TradingView. It shows that the market is closed with no trades and provides an overview of financial data. The content is primarily a data point display from a financial platform.

10x genomics CFO Adam Taich disposes of $2.99 million in company stock By Investing.com

https://m.au.investing.com/news/stock-market-news/10x-genomics-cfo-adam-taich-disposes-of-299-million-in-company-stock-93CH-4639404?ampMode=1
Adam Taich, CFO of 10x Genomics, Inc. (NASDAQ:TXG), sold approximately $2.99 million worth of company stock on September 9, 2026, under a Rule 10b5-1 trading plan. This transaction involved 46,388 shares sold at prices between $63.67 and $65.875, occurring as TXG stock neared its 52-week high after a significant 408% gain. Following the sale, Taich retains 316,344 shares, while the company recently reported strong Q2 2026 results surpassing analyst expectations, despite investor concerns about the Atera platform transition.

10x genomics CFO Adam Taich disposes of $2.99 million in company stock

https://m.investing.com/news/insider-trading-news/10x-genomics-cfo-adam-taich-disposes-of-299-million-in-company-stock-93CH-4898478?ampMode=1
Adam Taich, CFO of 10x Genomics, Inc. (NASDAQ:TXG), sold approximately $2.99 million worth of company stock on September 9, 2026, through a pre-arranged trading plan. This sale occurred as TXG stock was trading near its 52-week high after a significant 408% gain over the past year. Despite recent positive Q2 2026 earnings, analysts have mixed sentiments due to the company's transition to a new platform.

10x Genomics (NASDAQ: TXG) CEO lines up another share sale

https://www.stocktitan.net/sec-filings/TXG/144-10x-genomics-inc-sec-filing-5b87915330c5.html
10x Genomics CEO Serge Saxonov plans to sell 35,486 shares of Class A common stock, valued at approximately $2.2 million, through J.P. Morgan Securities LLC under Rule 144. These shares were acquired through RSU vesting and an option exercise. Saxonov previously sold 30,000 shares in June 2026 for over $1 million.
Advertisement

10x Genomics (TXG) CFO sells shares under preset trading plan

https://www.stocktitan.net/sec-filings/TXG/form-4-10x-genomics-inc-insider-trading-activity-342adb2b027b.html
10x Genomics (TXG) Chief Financial Officer, Adam Taich, sold a total of 46,388 shares of Class A Common Stock on September 9, 2026. The sales occurred in three open-market transactions at weighted average prices ranging from approximately $63.68 to $65.26, executed under a Rule 10b5-1 trading plan adopted on June 10, 2026. After these transactions, Adam Taich directly holds 316,344 shares of Class A Common Stock.

10x Genomics (TXG) director offloads 20,000 shares in open-market trades

https://www.stocktitan.net/sec-filings/TXG/form-4-10x-genomics-inc-insider-trading-activity-74009e8fd5e8.html
John R. Stuelpnagel, a director at 10x Genomics (TXG), sold 20,000 shares of Class A common stock on September 3, 2026, in open-market transactions. The shares were sold in three blocks at weighted average prices ranging from $60.66 to $62.61, totaling approximately $1.24 million. This transaction was not conducted under a Rule 10b5-1 trading plan.

T. Rowe Price reports 10%+ holding in 10x Genomics (TXG)

https://www.stocktitan.net/sec-filings/TXG/schedule-13g-10x-genomics-inc-passive-investment-disclosure-5-6c59cd1db43d.html
T. Rowe Price Associates, Inc. has disclosed an 11.7% beneficial ownership stake in 10x Genomics, Inc. (TXG), according to a Schedule 13G SEC filing. This amounts to 14,044,020 shares of Class A common stock, with T. Rowe Price asserting sole voting power over 13,511,751 shares and sole dispositive power over all 14,044,020 shares. Despite the disclosure, T. Rowe Price denies admission of beneficial ownership, stating the shares were acquired in the ordinary course of business and not for influencing control.

10x genomics CFO Adam Taich disposes of $2.99 million in company stock

https://www.investing.com/news/insider-trading-news/10x-genomics-cfo-adam-taich-disposes-of-299-million-in-company-stock-93CH-4898478
Adam Taich, CFO of 10x Genomics, Inc. (NASDAQ:TXG), sold 46,388 shares of company stock worth approximately $2.99 million on September 9, 2026, under a Rule 10b5-1 trading plan. This transaction occurred while TXG stock was near its 52-week high after a significant 408% gain over the past year, though InvestingPro analysis suggests the stock is currently overvalued. The company recently surpassed Q2 2026 revenue expectations but faced investor concerns about a near-term outlook shift due to its new Atera platform.

10x genomics director Stuelpnagel sells $1.2 million in shares By Investing.com

https://m.au.investing.com/news/stock-market-news/10x-genomics-director-stuelpnagel-sells-12-million-in-shares-93CH-4633278?ampMode=1
John R. Stuelpnagel, a director at 10x Genomics Inc. (NASDAQ:TXG), sold 20,000 shares of the company's Class A Common Stock for approximately $1.2 million on September 3, 2026. This insider sale occurs as TXG stock trades near its 52-week high after a significant 386% return over the past year. Despite recent positive financial results, including exceeding revenue expectations, the company is navigating a transition to its new Atera platform, with analysts maintaining a positive outlook.
Advertisement

10x genomics director Stuelpnagel sells $1.2 million in shares By Investing.com

https://ng.investing.com/news/stock-market-news/10x-genomics-director-stuelpnagel-sells-12-million-in-shares-93CH-2688508
John R. Stuelpnagel, a director at 10x Genomics Inc., sold approximately $1.2 million worth of company shares on September 3, 2026. This sale comes as the stock is near its 52-week high and is considered overvalued by InvestingPro analysis, despite recent positive Q2 2026 financial results and analyst optimism about its new Atera platform.

10x genomics director Stuelpnagel sells $1.2 million in shares

https://www.investing.com/news/insider-trading-news/10x-genomics-director-stuelpnagel-sells-12-million-in-shares-93CH-4892635
John R. Stuelpnagel, a director at 10x Genomics Inc. (NASDAQ:TXG), sold 20,000 shares of the company's Class A Common Stock for approximately $1.2 million on September 3, 2026. This insider sale occurred as TXG stock trades near its 52-week high, with InvestingPro analysis suggesting the stock is overvalued despite positive recent financial results and analyst ratings. The company recently surpassed Q2 2026 revenue expectations but faces a softer near-term outlook due to its transition to the new Atera platform.

10x genomics director Stuelpnagel sells $1.2 million in shares By Investing.com

https://uk.investing.com/news/stock-market-news/10x-genomics-director-stuelpnagel-sells-12-million-in-shares-93CH-4861528
John R. Stuelpnagel, a director at 10x Genomics Inc. (NASDAQ:TXG), sold over $1.2 million worth of shares on September 3, 2026. This insider sale occurred while TXG stock is trading near its 52-week high and is considered overvalued by InvestingPro analysis, despite analysts predicting a return to profitability this year. The company recently surpassed Q2 2026 revenue expectations but faces a softer near-term outlook with its transition to the Atera platform.

10x Genomics (TXG) CEO holds 1,075,249 shares after 100-share gift

https://www.stocktitan.net/sec-filings/TXG/form-4-10x-genomics-inc-insider-trading-activity-64e1fceb269b.html
10x Genomics (TXG) CEO Serge Saxonov reported a bona fide gift of 100 Class A shares on September 1, 2026, with a reported price of $0.00 per share. Following this transaction, Saxonov directly holds 1,075,249 Class A shares and also maintains indirect ownership through various trusts. No Rule 10b5-1 trading plan was associated with this gift.

10x Genomics (TXG) CEO sells 10,486 shares under 10b5-1 plan

https://www.stocktitan.net/sec-filings/TXG/form-4-10x-genomics-inc-insider-trading-activity-e569f36f9b2d.html
10x Genomics (TXG) CEO Serge Saxonov sold a total of 10,486 shares of Class A Common Stock on August 26, 2026, as part of a Rule 10b5-1 trading plan adopted in November 2025. The sales were executed in multiple transactions at weighted average prices ranging from approximately $62.53 to $64.99 per share. Saxonov also maintains indirect holdings of Class A shares through three trusts where he serves as trustee.
Advertisement

10x Genomics CEO Serge Saxonov sells $667,900 in stock

https://www.investing.com/news/insider-trading-news/10x-genomics-ceo-serge-saxonov-sells-667900-in-stock-93CH-4881888
Serge Saxonov, CEO of 10x Genomics (NASDAQ:TXG), sold 10,486 shares of Class A Common Stock worth approximately $667,900 on August 26, 2026, pursuant to a pre-arranged trading plan. This sale occurred as TXG shares were near a 52-week high, despite the company recently exceeding Q2 2026 revenue and adjusted EPS expectations. Analysts have maintained a Buy rating on TXG, increasing price targets due to potential growth in AI and biopharma sectors.

10x Genomics CEO Serge Saxonov sells $667,900 in stock By Investing.com

https://ng.investing.com/news/stock-market-news/10x-genomics-ceo-serge-saxonov-sells-667900-in-stock-93CH-2679475
10x Genomics CEO Serge Saxonov sold 10,486 shares of Class A Common Stock worth approximately $667,900 on August 26, 2026, executed under a Rule 10b5-1 trading plan. The sale occurred as the company's shares traded near their 52-week high, despite the stock appearing overvalued according to InvestingPro analysis. Saxonov still retains significant direct and indirect ownership in the company.

10x Genomics President Benjamin J. Hindson Sells Shares to Meet Tax Withholding Requirements

https://kalkinemedia.com/us/news/announcements/10x-genomics-president-benjamin-j-hindson-sells-shares-to-meet-tax-withholding-requirements
Benjamin J. Hindson, President and Chief Scientific Officer of 10x Genomics, Inc. (NASDAQ:TXG), sold 13,818 shares of Class A Common Stock on August 24, 2026. This sale was conducted to satisfy tax withholding obligations related to the vesting of restricted stock units. After the transaction, Hindson retains beneficial ownership of 488,182 Class A Common Stock shares.

10x Genomics CEO Serge Saxonov Sells 18,545 Shares to Cover RSU Tax Withholding

https://kalkinemedia.com/us/news/announcements/10x-genomics-ceo-serge-saxonov-sells-18545-shares-to-cover-rsu-tax-withholding
Serge Saxonov, CEO and Director of 10x Genomics, Inc., sold 18,545 shares of Class A Common Stock on August 24, 2026. This transaction was executed to fulfill tax withholding obligations stemming from the vesting of restricted stock units. Post-sale, Saxonov directly holds 1,085,835 Class A Common Stock shares, with additional indirect holdings through various trusts.

10x Genomics (NASDAQ: TXG) holder to sell 2,207 RSU shares

https://www.stocktitan.net/sec-filings/TXG/144-10x-genomics-inc-sec-filing-f2097ed372ef.html
Shehnaaz Suliman, a holder of 10x Genomics (NASDAQ: TXG), plans to sell 2,207 shares of Class A common stock acquired through RSU vesting, with J.P. Morgan Securities LLC handling the sale. The aggregate market value of these shares is $143,719.84. This Form 144 filing also notes Suliman previously sold 5,723 shares for $186,756.21 within the last three months.
Advertisement

10x Genomics (TXG) CEO gifts 4,000 shares in stock donation

https://www.stocktitan.net/sec-filings/TXG/form-4-10x-genomics-inc-insider-trading-activity-b475f6d16546.html
10x Genomics, Inc. CEO Serge Saxonov reported a bona fide gift of 4,000 shares of Class A Common Stock on August 20, 2026. After this transaction, he directly holds 1,104,380 Class A shares and has indirect holdings through several family trusts where he serves as trustee. The gift was made without expectation of repayment and was not part of a Rule 10b5-1 trading plan.

Price to sales forward of 10x Genomics Inc Class A – MUN:1KJ

https://www.tradingview.com/symbols/MUN-1KJ/financials-statistics-and-ratios/price-sales-fwd/
This page provides financial information for 10x Genomics Inc Class A (MUN:1KJ) on the Munich Stock Exchange, specifically focusing on its forward price-to-sales ratio. The content is primarily a navigation and information hub, indicating the stock market status and various available financial tools and data provided by TradingView and its partners.

ETFs Investing in 10x Genomics Inc Class A Stocks

https://www.tradingview.com/symbols/LS-A2PPQJ/etfs/
This article provides a comprehensive list of Exchange Traded Funds (ETFs) that hold 10x Genomics Inc Class A stocks, organized by market value. It details various ETFs, including their issuers, management styles, expense ratios, AUM, price changes, and 3-year NAV total returns, offering investors a broad overview of investment options for this stock.

10x Genomics (NASDAQ: TXG) director sells under 10b5-1 plan

https://www.stocktitan.net/sec-filings/TXG/form-4-10x-genomics-inc-insider-trading-activity-4bfe75b60814.html
10x Genomics (NASDAQ: TXG) director Sarah A. Teichmann reported two open-market sales of Class A Common Stock, totaling 7,551 shares. These transactions, executed on August 13 and August 14, 2026, were conducted under a Rule 10b5-1 trading plan adopted on May 14, 2026. The sales amounted to approximately $432,000, leaving Teichmann with 28,058 shares of Class A Common Stock.

ARK Investment Management (TXG) reports 10.0M-share position in 10x Genomics

https://www.stocktitan.net/sec-filings/TXG/schedule-13g-a-10x-genomics-inc-amended-passive-investment-disclosure-6c773f10543b.html
ARK Investment Management LLC and its CEO, Catherine D. Wood, have reported a beneficial ownership of 10,003,058 shares of 10x Genomics, Inc. Class A common stock as of June 30, 2026. This position represents an 8.56% stake in the company's outstanding Class A shares. The filing details the sole and shared voting and dispositive powers held by ARK and Wood over these shares.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement